Skip to content

Role of palliative radiation therapy in gallbladder cancer.

A pilot study to evaluate the impact of palliative radiotherapy in upfront inoperable/chemo unfit patients with extrahepatic biliary tract tumors.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039390
Enrollment
15
Registered
2022-01-13
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K87- Disorders of gallbladder, biliarytract and pancreas in diseases classified elsewhere

Interventions

Intervention1: Palliative Radiotherapy: Palliative radiotherapy will be given in patients of gallbladder cancer after informed consent, who are not fit for surgery or chemotherapy. Intervention2: Pal

Sponsors

PGIMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: (i) Pathologically proven gallbladder and bile duct malignancy (ii)Willing to participate in the study. (iii) Not fit for definitive surgery or chemotherapy.

Exclusion criteria

Exclusion criteria: (i) Postop patients. (ii) Previous exposure to radiotherapy or chemotherapy I (iii) Pregnant women.

Design outcomes

Primary

MeasureTime frame
Primary Outcome- To look for a change in obstructive mass size at 4 weeks after CRT and acute and late toxicities, if any.Timepoint: 1.Size of mass on CECT as per RECIST criteria 1.1 Before and after 4 weeks of radiation therapy. 2.Acute toxicities will be assessed during the radiation therapy and uptil 6 months of CRT while chronic toxicities shall be assessed after 6 months of completion of radiation therapy.

Secondary

MeasureTime frame
To look for PTBD/stent patency status post CRT, Quality of life (QOL) and 1-year overall survival (OS).Timepoint: 1. PTBD/Stent status shall be assessed after 4 weeks of completion of radiation therapy. 2.QOL shall be assessed before and at 4weeks of completion of radiotherapy and then on subsequent follow ups for 1 year. 3.Survival at 1 year shall be recorded.

Countries

India

Contacts

Public ContactDivyesh Kumar

Post Graduate Medical Education and Research

divyeshanand1@gmail.com7087441314

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026